Scientific programme

Opening

9:00

Orla Hardiman

Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland

9:30

Understanding the heterogeneity of ALS – A novel multimodal approach

Javier Riancho

Department of Neurology, Hospital Sierrallana-IDIVAL, Torrelavega, Spain

10:15

Environmental factors and amyotrophic lateral sclerosis

coffee-break

11:00

Francisco Gil Bea

Department of Neurology, University Hospital Donostia, Biodonostia Health Research Institute, CIBERNED, San Sebastián, Spain

11:30

Dissecting a metabolic hypothesis for amyotrophic lateral sclerosis

Markus Otto

Department of Neurology, University of Ulm, Ulm, Germany

12:15

Neurochemical markers for diagnosis, onset and prognosis of ALS

Alberto García Redondo

Biochemistry Department, CIBERER U-723. Health Research Institute, October 12th Hospital, Madrid, Spain

13:00

Fine tunning a molecular diagnosis algorithm for patients with ALS and FTD

Poster Session and Lunch

13:45

Adrian M Isaacs

Department of Neurodegenerative Disease, UCL Institute of Neurology, London, UK

15:30

C9orf72 ALS/FTD: molecular mechanisms

Emanuele Buratti

International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy

16:15

Using TDP-43-modifier genes to better understand pathology and explore therapeutic options

coffee-break

17:00

Caroline Rouaux

INSERM, UMR-S1118, University of Strasbourg, Strasbourg, France

17:30

Unravelling the molecular mechanisms behind corticospinal neuron degeneration in ALS

Robert H Baloh

Department of Neurology, Center for Neural Science and Medicine, Los Angeles, CA, USA

18:15

ALS genes that alter innate immune function and neuroinflammation

Rosario Osta

LAGENBIO, Veterinary Faculty, IIS Aragón, University of Zaragoza, CIBERNED, Zaragoza, Spain

9:00

The long road from preclinical trials to the patient: Insights from 20 years of research on SOD1G93A mice in LAGENBIO

Ana Martínez

Department of Chemical and Physical Biology , Centro de Investigaciones Biológicas (CIB)-CSIC, CIBERNED, Madrid, Spain

9:45

Protein kinase inhibitors as a new therapeutic approach for ALS

Ludo Van Den Bosch

KU Leuven - University of Leuven, Department of Neurosciences, Laboratory of Neurobiology and Experimental Neurology, Leuven, Belgium

10:30

Modulation of axonal transport as a therapeutic strategy in motor neuron diseases

coffee-break

11:15

Eva de Lago

Department of Biochemistry and Molecular Biology, Faculty of Medicine, Complutense University, CIBERNED, IUIN, Madrid, Spain

11:45

Targeting the CB2 receptor to delay disease progression in ALS: studies in experimental models

Xavier Navarro

Institute of Neurosciences and Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona, CIBERNED, Bellaterra, Spain

12:30

Gene therapy strategies for neuroprotection in ALS

Poster Session and Lunch

13:15

Jeff D Rothstein

Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA

15:00

Disassembly and reassembly of the nuclear pore in C9 ALS/FTD and sporadic ALS: target for unique therapy

Closing

15:45

Download Programme